Chihuahua, Chihuahua, Mexico, 11 CELLTRION, Inc., Incheon, Korea, Republic Of Ba ckg ro u n d : CT-P13 is a biosimilar to innovator infliximab (INX) approved by the European M edicines Agency. From the PLANETRA, which is randomized, double-blind, active-controlled trial to assess efficacy and safety of CT-P13 in rheumatoid arthritis (RA) patients, therapeutic equivalence was demonstrated via the primary endpoint (ACR20 at Week30) 1 . Several secondary endpoints exist that can capture valuable information to the clinician.
Ob j e cti ve s: To compare efficacy via the DAS28, CDAI, and SDAI of CT-P13 and INX in patients with RA and effect of anti-drug antibody (ADA) on the clinical outcome measures.
Me th o d s:
In PLANETRA, 606 patients with RA were treated with either 3 mg/kg of CT-P13 or INX with methotrexate at usual schedule up to Week 54. Key secondary endpoints were CDAI, SDAI, and DAS28. ADA was measured at baseline and at Week 14, 30 and 54 by an electrochemiluminescent assay.
R e su l ts: The mean baseline DAS28 scores reflected high disease activity (DAS28-ESR, 6.7 vs 6.6; DAS28-CRP, 5.9 vs 5.8; CT-P13 vs INX). The mean change in DAS28-ESR over 54 weeks was -2.4 in both treatment groups. 
